06/26/20 8:30 AM EDT — Casimersen is designed for the treatment of exon 45 amenable patients, approximately eight percent of patients with Duchenne — — Casimersen is the third exon-skipping […]
During this webinar, you will learn about NS Pharma, Inc. (a wholly owned, US subsidiary of Nippon Shinyaku Co., Ltd. based in Kyoto, Japan), focused on developing innovative treatments for […]
Newport Beach, CA, June 15, 2020 – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today that Joanna Kemp, BSN, RN, […]
06/15/20 11:00 AM EDT — Results at one year demonstrate continued safety and tolerability of SRP-9001 micro-dystrophin gene therapy in four patients with Duchenne muscular dystrophy — — Confirmed vector […]
Kyoto, Japan, June 8, 2020 – Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Kyoto; President, Shigenobu Maekawa) announced that European Commission (EC) has granted Orphan Drug Designation to viltolarsen (NS-065/ NCNP-01) […]
Pratteln, Switzerland, June 2, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed a long-term, open-label extension study of 24 months duration with vamorolone in […]
May 20, 2020 Dear Duchenne community, As you know from our previous updates, Santhera’s main focus in the U.S. in the first half of the year has been to bring […]
Friday, May 15, 2020 – 8:00amEDT Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy […]
Newport Beach, CA, May 15, 2020 – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, congratulates Pfizer for announcing data from subjects […]
